Clinical-stage company developing a new generation of adoptive cell therapies for cancers, with a focus on addressing primary mechanisms of resistance to CAR-T therapies.
Cargo Therapeutics
Oncology
Total Addressable Market
Red Tree Board Member(s)
Red Tree Board Member
Heath Lukatch, Ph.D.
Affiliated with Red Tree SAB Member
Red Tree Participation
Co-investor in seed round, co-led bridge round, co-investor in Series A
